Approval
EU adds axial spondyloarthritis to Alfasigma's Jyseleca label
The European Commission cleared filgotinib for adults with axial spondyloarthritis, in either its radiographic or non-radiographic form, after inadequate response to conventional care. Across the OLINGUITO phase 3 program, more patients reached ASAS40 at week 16 on the JAK1-preferring drug than on placebo, with gains holding to week 52. A UK filing is pending.
- Drugfilgotinib
- CompanyAlfasigma
- TargetJanus Kinase 1
- TargetTyrosine-protein kinase JAK2
- TrialNCT05785611
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.
